Introduction
My topic today is, Can in vitro studies assist us in species extrapolation? And I'm going to narrow this topic a little bit simply by concentrating on human data, thinking that is the species that we're most interested in. I would like to redefine the question and ask, Can in vitro studies or in vivo-in vitro studies be used to assess human genotoxicity?
I'd like to start with a quote from Dr. James Miller and just read this for the group: I do not think we can rely on extrapolation of data on chemical carcinogens from experimental animnals to humans no matter how sophisticated or plausible these extrapolations may seem, until we know more about the chemical carcinogenesis in humans.
There are a lot of ways to take this idea as the springboard for leading into the discussion, but I think one of the most direct ways is to try to glean what we can from the use of human cells in the short-term assays and try to make species extrapolations based on the short-term in vitro studies that one can do with human cells. So the question that I'd like to address instead of just, can in vitro studies be useful for risk assessment, is to ask, Are human cells going to be useful for risk assessment purposes?
I have an idea based on some of my own research and research from many other laboratories that the answer to that question might be yes. But today I will point out the research that has been done and the rationale for the types of studies that have been done so far. This is a very timely topic, the use of human cells for carcinogenesis studies, as the January 1 If it can be determined through investigations with laboratory animals that for a particular chemical carcinogen, the routes of activation and detoxification of the chemical by cells in vitro is similar or identical to that observed when the investigations are conducted in vivo, and ifthe spectrum of adducts that one can identify on DNA isolated from a tissue from animals exposed to a particular compound are the same as the types of adducts one finds when cells from that tissue are exposed to the compound in culture, one has established a scientific basis for making the extrapolation from in vitro to in vivo for that laboratory animal.
To investigate the potential human genotoxicity, one would have to rely heavily on the data from animal models. For example, if it was determined that rats of a certain strain metabolize compound "A" in a manner which results in a certain profile of adducts on hepatocyte DNA, and it was then determined that compound A induced liver tumors in that strain of rat, one could investigate the routes of metabolism and the types of DNA adducts produced on human hepatocytes exposed in culture to compound A. If it were found that hepatocytes, isolated from a number of human cases, metabolized the compound in exactly the same way as the rodent, and the same profile of DNA adducts were produced by rodent and human hepatocytes, one would have a scientific basis for concluding that there is a potential for human genotoxicity from compound A. Whether that potential is ever realized may depend on the exposure of the initiated cells to tumor promoters or other modifying factors. Since cancer is a multistep process, which may involve induction of mutations, chromosomal changes, and the response ofinitiated cells to tumor promoters, it may be unrealistic to believe that any one short-term in vitro assay could faithfully predict the carcinogenicity of all possible chemicals in a whole animal. Just as one cannot measure the activation of protein kinase C with a cyclic-AMP assay, one will not be able to accurately predict the carcinogenicity of chemicals which are not mutagens with a mutagenesis assay. If one simply understands the limitations of each of the short-term assays, one can use that data in a more meaningful way for risk assessment purposes.
I think that the use of human cells for the standard types of genetic toxicology research is intuitively logical. There are certain situations where the short-term assays are going to fall short of being predictive of full carcinogenesis. In particular, human cells may not express the full biological response of exposure to carcinogens, e.g., transformation. This is an area where short-term assays may fall short. However, this is not just true with human cells but with cells from many other species. Many tissues may not be useful for initiation-promotion protocols in vitro. And the multistep aspects of carcinogenesis may be very hard to define using only a single-cell type of culture. The interspecies differences in carcinogen metabolism and DNA adducts have been discussed in several reviews and discussions (2) (3) (4) (5) . But I think that the general consensus is that human cells in general form the same types of metabolites as rat cells. There may be quantitative differences in the amounts of specific metabolites or specific DNA adducts produced by these two species, but not dramatic qualitative differences in the exact types of metabolites that are produced or in the exact types of adducts that are produced. Human cells may also be used for risk assesesment purposes for fine tuning the interpretation of data by asking at a certain level of DNA adducts, Can one expect to observe a genotoxic event? as opposed to simply asking the question, Is this chemical going to be genotoxic in this species?
The last point I'd like to discuss is the multistep area of carcinogenesis and emphasize the newer areas of research, including those involving oncogenes. Activated human oncogenes transform rat cells quite well. Therefore, there may be common pathways to transformation between the species. If one determined that exposure to a particular chemical induced the activation of oncogenes in the liver of a rat, that data may be very relevant to the activation of those same oncogenes in other species, including humans.
However, there are some aspects of carcinogenesis research that can only be addressed with human tissues. Whereas many rat or mouse cells seem to be transformed quite well by transfection of oncogenes, when one puts those same activated oncogenes into human cells, they don't result in the transformation of the cells. There are numerous examples of this in the literature. Experiments have been reported in which mutated ras genes, alone or in combination with other cooperating genes such as the myc gene, have been transfected into human cells (6) . The phenotype that results from these experiments with oncogene transfected human cells indicates that the human cells are more difficult to transform with cloned oncogenes than the rodent cells, suggesting that there may be repressor genes in the human cells that antagonize the action of the activated oncogenes. Therefore, the full biological response to oncogene activation in human cells may be slightly different than that observed following the activation of oncogenes in rodent cells. And, again, the problem with the liver, which I'm more familiar with, is that there are certain ways to get around some of these problems. With the liver one can put compounds like phenobarbitol in culture and it seems to maintain the viability of the cells up to many weeks in certain instances. DMSO and coculture techniques, when hepatocytes are maintained in culture with liver epithelial cells, can prolong the differentiated state of these cells in culture for weeks to months. So I think it's very likely that as cell culture techniques are improved and more research is done, that even in the tissues such as the endocrine tissues, one will be able to prolong the viability and differentiated state of many epithelial tissues in vitro.
UNKNOWN SPEAKER: Has anybody tried the use of nude animals, that is, immunologically deficient animals, to compare the responses of human tissues as tissues rather than as cells compared to animal cells as a basis for species extrapolation at least of toxic effect? DR. STROM: Do you mean by transplantation of human tissues into the nude mouse? Is that what you mean?
UNKNOWN SPEAKER: Yes. DR. STROM: I'm not aware of that being done on any grand scale. There are certain instances where human skin was put on the back of nude mice and someone tried TPA promotion experiments. The situation is that there are certain strains of mice that are easily promoted by TPA and work well on initiation-promotion protocols. Whereas, in other strains of mice, the initiation-promotion protocol with TPA on the back of the mouse skin doesn't work all that well. And when the experiments were done with the human skin, TPA was found to be a weak promoter. I think this points out the fact that work with the human tissues themselves really has to be done even if it isn't in the transplant situation in the nude mouse. Because there are certain differences that one sees between different species and their susceptibility to cancer. And it can only be addressed by using that particular tissue. And when one comes up with a compound that can induce tumors in mice or rats and we're trying to extrapolate it to humans, we have to determine whether we are mice or rats. And some of the ways, as Dr. Butterworth has said, that this might be done is to look at the mechanistic approach. Do they make the same metabolites? Do they make the same adducts? Are they repaired at the same rate? And so on, with everything that may affect the carcinogenicity of the compound, including cell turnover. Experiments can then be done to address these points to make the interspecies extrapolation. But, again, the interspecies extrapolation is probably only as good as the data that one can get in the short-term assays.
DR. ALBERT: We'll move on to the next area, which is, How do we predict toxicity of complex mixtures?
